Back to all news
AI-Driven Blood Test Shows Success in Early Liver Cancer Detection Across Populations
Researchers validate an AI-powered cfDNA blood test that detects liver cancer accurately across diverse populations, enhancing early detection efforts.
Key Details
- 1The DELFI liquid biopsy platform uses cfDNA fragmentome analysis with AI to detect liver cancer.
- 2Validated on 377 participants from Guatemala and Romania with varying liver cancer causes (viral, metabolic, aflatoxin).
- 3Test performed consistently well across distinct genetic and environmental backgrounds.
- 4Combined with AFP and clinical risk factors, it outperformed standard blood tests for early and late-stage disease.
- 5MethID technology traced DNA fragment origins, showing signals not just from tumors but also liver, blood vessel, and immune cells.
- 6DELFI Diagnostics received funding, and several inventors have patents and equity ties to relevant companies.
Why It Matters
Reliable, noninvasive early detection of liver cancer remains an unmet clinical need, especially since standard methods miss many tumors. This study demonstrates the potential of AI-driven cfDNA assays to generalize across populations, foreshadowing broader multi-disease detection capabilities for the radiology and cancer screening community.
Source
EurekAlert
Related News
•EurekAlert
AI System Enhances Cancer Cell Detection via Light Scattering Spectra
Japanese researchers developed an AI system using light scattering spectra to improve cancer cell identification in cytology.
•EurekAlert
AI and X-ray Imaging Reveal Lost Texts in Ancient Roman Scrolls
AI and x-ray technology enable scientists to virtually read previously unreadable, carbonized Roman scrolls from Herculaneum.
•EurekAlert
AI’s Potential to Expand, Not Shrink, the Clinical Workforce
AI advancements may lead to more, not fewer, healthcare jobs, challenging common fears about workforce reductions in specialties like radiology.